Question
Untitled item
S6W-05117 · Written Question · lodged by Sweeney, Paul
Lodged on
13 Dec 2021Heard / answered on
23 Dec 2021To ask the Scottish Government what information it has on the current legal status of the drug, Paxlovid, in Scotland; how much of the drug NHS Scotland has (a) ordered and (b) stocked; what models it is aware of regarding its efficacy in reducing hospitalisations of patients with the Omicron variant of COVID-19, and what emergency processes are underway for scaling manufacture and distribution of the drug within a 48-hour period.
The answer
The Scottish Government continues to closely monitor all emerging evidence on the effectiveness of COVID-19 treatments and their clinical effectiveness. The Medicines and Healthcare products Regulatory Agency (MHRA) is now assessing Paxlovid’s safety and effectiveness, and I cautiously welcome analysis of the final clinical trial results from Pfizer (which are yet to be published or verified) which show that Paxlovid cuts the risk of hospitalisation or death by approximately 89% in high risk, non-hospitalised adult patients with mild-to-moderate COVID-19. If approved by the MHRA, this will represent another significant pharmaceutical option in our response to COVID-19.
On 20th October, the UK Government announced that 250,000 treatment courses of Paxlovid had been ordered, pending regulatory approval. On 22nd December, the UK Government announced that a further 2.5 million treatment courses had been ordered as part of efforts to reduce the impact of COVID-19 and the Omicron variant across the UK. If authorised by the MHRA, the intention is to initially deploy antivirals such as Paxlovid to individuals through a UK-wide national study, funded by the National Institute for Health Research (NIHR). The University of Oxford has been selected to lead the study . This will enable collection of additional data to address limitations in the company-sponsored trials, for example the effectiveness of the treatments in vaccinated patients, as participants in the company trials were unvaccinated.
On 20th October, the UK Government announced that 250,000 treatment courses of Paxlovid had been ordered, pending regulatory approval. On 22nd December, the UK Government announced that a further 2.5 million treatment courses had been ordered as part of efforts to reduce the impact of COVID-19 and the Omicron variant across the UK. If authorised by the MHRA, the intention is to initially deploy antivirals such as Paxlovid to individuals through a UK-wide national study, funded by the National Institute for Health Research (NIHR). The University of Oxford has been selected to lead the study . This will enable collection of additional data to address limitations in the company-sponsored trials, for example the effectiveness of the treatments in vaccinated patients, as participants in the company trials were unvaccinated.
Answered by Humza Yousaf on 23 Dec 2021.